The war in the Middle East has thrown a wrench into one of the most critical and least visible pipelines in global health: the pharmaceutical supply chain. Major air cargo hubs in Dubai, Abu Dhabi, and Doha — transit points that link European drug manufacturers with markets across Asia, Africa, and the Gulf — have been shut down or repeatedly disrupted by the escalating U.S.-Israeli conflict with Iran and subsequent Iranian retaliatory strikes. The result is a scramble among drugmakers, logistics providers, and hospital systems to find alternative routes before stockpiles run dry. The situation is already pressing.
According to industry data cited by Wouter Dewulf, a professor at Antwerp Management School, more than one-fifth of global air cargo is exposed to Middle East disruption. That figure matters enormously for pharmaceuticals, because air freight is the primary transport method for life-saving drugs and vaccines that require temperature control and fast delivery. Cancer drugs, generics flowing through the Strait of Hormuz, and cold chain shipments are all in the crosshairs. Some customers in the Gulf have warned suppliers they could run low on cancer medicines within four to six weeks. This article breaks down which drugs face the highest risk, how pharmaceutical companies are rerouting shipments, why cold chain integrity is so difficult to maintain on alternative routes, and what the knock-on effects look like for American consumers who depend on affordable generic medications.
Table of Contents
- Why Are Pharmaceutical Supply Chains Running Through the Middle East So Vulnerable to Disruption?
- Which Drugs Face the Greatest Shortage Risk and What Are the Limits of Current Stockpiles?
- How the Strait of Hormuz Standoff Threatens America’s Generic Drug Supply
- How Drugmakers Are Rerouting Shipments and What the Tradeoffs Look Like
- Why Cold Chain Failures Could Turn a Logistics Problem Into a Patient Safety Crisis
- Packaging Materials and Components Add a Hidden Layer of Vulnerability
- What Comes Next for Global Pharmaceutical Logistics
- Conclusion
- Frequently Asked Questions
Why Are Pharmaceutical Supply Chains Running Through the Middle East So Vulnerable to Disruption?
The answer comes down to geography and infrastructure. Over the past two decades, the Gulf states invested heavily in becoming global logistics hubs. Dubai, Abu Dhabi, and Doha built world-class airports with massive cold storage facilities specifically designed to handle pharmaceutical cargo. These hubs sit at the intersection of routes connecting European manufacturers — particularly in Switzerland, Germany, and Ireland — with fast-growing markets in South Asia, Southeast Asia, and sub-Saharan Africa. When those hubs go offline, there is no simple substitute. You cannot just reroute a temperature-sensitive cancer drug the way you might reroute a container of electronics.
The exposure is staggering in scale. More than 20 percent of global air cargo passes through or depends on Middle Eastern transit points, according to figures cited by Professor Dewulf. For pharmaceuticals specifically, the concentration may be even higher, because drugmakers optimized their logistics around these hubs for speed, cost, and cold chain reliability. The specialized infrastructure — temperature-controlled warehouses, dedicated pharmaceutical handling protocols, and customs fast-tracking for medical shipments — took years to build and cannot be replicated overnight at alternative airports in Istanbul or Jeddah. Compare this to the Red Sea shipping disruptions caused by Houthi attacks in 2024, which primarily affected sea freight. That crisis was serious but pharmaceuticals were somewhat insulated because most high-value, time-sensitive drugs move by air. This time, the disruption hits air cargo directly, which means the drugs most in need of fast, controlled transport are the ones most affected.
Which Drugs Face the Greatest Shortage Risk and What Are the Limits of Current Stockpiles?
Cancer drugs top the list. Prashant Yadav, a senior fellow for global health at the Council on Foreign Relations, has identified monoclonal antibodies — a class of targeted cancer therapies — as among the highest-risk products. These drugs require strict refrigeration throughout the entire supply chain, have relatively short shelf lives, and cannot tolerate the kind of delays and additional handling that come with rerouted shipments. A monoclonal antibody that sits on a tarmac for six extra hours in an uncontrolled environment may be rendered useless. Typical stock levels for cancer medicines in the Gulf run approximately three months. That sounds like a reasonable buffer until you consider how quickly it erodes.
Some customers have already warned their suppliers they could run low within four to six weeks if current conditions persist. The gap between “three months of stock” and “six weeks to shortage” reflects the reality that supply chains are not static — hospitals and pharmacies are constantly drawing down inventory while expecting regular replenishment that is no longer arriving on schedule. However, if you are a patient in the United States or Western Europe, the immediate risk is different. The direct shortage threat is most acute in Gulf countries and markets that depend on Gulf transit hubs. american patients face a separate but related risk through the Strait of Hormuz, which we address below. The important caveat is that global pharmaceutical supply is interconnected — a shortage in one region can trigger hoarding and panic buying in others, which cascades unpredictably.
How the Strait of Hormuz Standoff Threatens America’s Generic Drug Supply
While cancer drugs in the Gulf grab headlines, American consumers face their own supply chain threat from the standoff at the Strait of Hormuz. This narrow waterway between Iran and the Arabian Peninsula is one of the world’s most important shipping corridors, and the current military tensions have made transit through it unreliable at best and dangerous at worst. CNBC reported on March 16, 2026, that the standoff is putting the supply of America’s generic drug prescriptions at risk. The connection between a Middle Eastern shipping lane and your local pharmacy is more direct than most people realize. India is the world’s largest supplier of generic medications, and a significant volume of raw pharmaceutical ingredients — known as active pharmaceutical ingredients, or APIs — flow through or near the Strait of Hormuz on their way from manufacturing plants in India and China to markets worldwide.
When that corridor is threatened, the entire economics of generic drug manufacturing gets disrupted. Shipping insurance rates spike, vessels are rerouted around the Cape of Good Hope adding weeks to transit times, and costs rise at every step. For a concrete example, consider a common generic blood pressure medication manufactured in India. The API may originate in China, ship to an Indian formulation plant, and then the finished product travels by sea through routes that pass near or through the Strait of Hormuz on its way to American distributors. Every additional day of transit, every insurance surcharge, and every rerouting fee ultimately gets passed along — either as higher prices or, if manufacturers cannot absorb the costs, as supply decisions that prioritize higher-margin markets over lower-margin generic contracts.
How Drugmakers Are Rerouting Shipments and What the Tradeoffs Look Like
Pharmaceutical companies are not sitting idle. According to Reuters, drugmakers are actively rerouting shipments through alternative airports and overland routes. The primary alternatives include Jeddah and Riyadh in Saudi Arabia, Istanbul in Turkey, and airports in Oman. For longer-haul cargo that previously transited through Gulf hubs, some shipments are being shifted through China and Singapore. Overland trucking is also being used to reach final markets in the Gulf when air routes are unavailable. Dorothee Becher, head of air logistics for healthcare at Kuehne+Nagel, stated that carriers are currently reaching Gulf markets through these alternative routes and that healthcare cargo is being prioritized over other freight categories. Major shortages have not yet materialized, which is the one piece of genuinely good news in this situation.
But “not yet” is doing a lot of heavy lifting in that sentence. The tradeoffs are significant. Rerouting through Istanbul or Jeddah adds transit time, requires additional handling, and introduces new customs checkpoints — each of which is a potential failure point for temperature-sensitive drugs. Shifting cargo through Singapore or China means substantially longer flight times and higher fuel costs. Overland trucking through the Arabian Peninsula exposes shipments to desert heat and road conditions that are far less controlled than an airport cold storage facility. Every alternative is worse than the original route in at least one dimension — cost, speed, reliability, or cold chain integrity. The question is whether “worse but functional” can hold until the original routes reopen, and nobody knows the answer to that.
Why Cold Chain Failures Could Turn a Logistics Problem Into a Patient Safety Crisis
The cold chain — the unbroken series of refrigerated storage and transport links that keeps temperature-sensitive drugs viable from factory to patient — is the most fragile element of this entire situation. As Pharmaceutical Commerce reported in March 2026, alternative cold chain corridors “cannot be set up overnight,” and temperature-controlled shipments risk spoilage with every added transfer, storage stop, and customs handoff along replacement routes. This is not an abstract risk. A biologic drug like a monoclonal antibody typically must be maintained between 2 and 8 degrees Celsius throughout its journey. A single excursion outside that range — even for a few hours — can degrade the drug’s efficacy or render it unsafe.
When you add an extra stopover in Istanbul, a customs hold in Jeddah, and a truck transfer to a final destination in Bahrain, you have introduced three additional points where the cold chain can break. Each handoff requires loading and unloading from temperature-controlled environments, and each customs checkpoint introduces unpredictable delays. The warning here is straightforward: even if pharmaceutical companies successfully reroute every shipment, the drugs that arrive may not all be safe to use. Quality control and temperature monitoring become exponentially more important — and more difficult — when routes are improvised under pressure. Hospitals and pharmacies receiving shipments through alternative channels need to be especially vigilant about checking temperature logs and verifying chain-of-custody documentation. A drug that arrived is not necessarily a drug that works.
Packaging Materials and Components Add a Hidden Layer of Vulnerability
The disruption extends beyond finished drugs. Reuters and Pharmaceutical Commerce have reported that shipping disruptions also threaten pharmaceutical components and packaging materials, including vial stoppers, IV bag plastics, and other items essential for drug manufacturing and packaging. This is the kind of second-order effect that does not make headlines until it causes a factory shutdown. Consider a vaccine manufacturer in Europe that sources rubber vial stoppers from a supplier in Southeast Asia.
Those stoppers may have previously traveled through a Gulf air hub as part of a consolidated cargo shipment. With that route disrupted, the stoppers arrive late — or not at all — and the vaccine production line sits idle even though every other ingredient is available. The same logic applies to IV bag plastics, blister pack materials, and the specialized films used in transdermal patches. A pharmaceutical supply chain is only as strong as its weakest component, and many of those components travel the same disrupted routes as the finished drugs.
What Comes Next for Global Pharmaceutical Logistics
The longer this conflict persists, the more permanent the changes to pharmaceutical supply chains will become. Companies that are currently treating rerouted shipments as temporary workarounds will eventually begin building redundant infrastructure at alternative hubs. Istanbul, Jeddah, and Singapore could see significant investment in pharmaceutical-grade cold storage and handling facilities. That diversification would ultimately make the global supply chain more resilient, but it will take years and cost billions — costs that will be reflected in drug prices.
In the near term, the situation remains precarious. Direct Relief has reported that the escalating conflict is straining regional health systems and disrupting humanitarian supply routes, which means the most vulnerable populations — refugees, patients in conflict zones, and communities dependent on aid shipments — are bearing the heaviest burden. For American consumers, the Strait of Hormuz threat to generics is the most immediate concern. Policymakers, pharmaceutical executives, and logistics providers are all watching the same clock: the four-to-six-week window before current stockpiles in the Gulf begin running out, and the unpredictable timeline for when — or whether — the original supply routes will reopen.
Conclusion
The pharmaceutical supply chain disruption caused by the Middle East conflict is a slow-moving crisis with fast-approaching deadlines. More than 20 percent of global air cargo is exposed, cancer drugs and biologics face the most acute shortage risk, America’s generic drug supply is threatened by the Strait of Hormuz standoff, and cold chain integrity is degrading with every improvised rerouting. Logistics providers say the system is holding for now, but “for now” has an expiration date measured in weeks, not months.
Patients, healthcare providers, and policymakers should be paying close attention. If you depend on a medication that requires refrigeration or is manufactured with components sourced from Asia, talk to your pharmacist about supply timelines. Healthcare systems should be auditing their inventory buffers and identifying which drugs are most exposed to these disruptions. And anyone watching the geopolitical situation should understand that the humanitarian cost of this conflict extends far beyond the battlefield — it reaches into hospitals, pharmacies, and medicine cabinets around the world.
Frequently Asked Questions
Which medications are most at risk from the Middle East supply chain disruption?
Cancer drugs — particularly monoclonal antibodies and other biologics requiring strict refrigeration — face the highest risk. Medications with short shelf lives and those requiring continuous cold chain transport are most vulnerable because they cannot tolerate the delays and additional handling caused by rerouted shipments.
Will this affect drug prices in the United States?
It is likely to put upward pressure on generic drug prices specifically. The Strait of Hormuz standoff threatens shipping routes for generic medications and active pharmaceutical ingredients flowing from India and China. Higher shipping costs, insurance surcharges, and rerouting expenses get passed along through the supply chain, though the full impact on consumer prices may take weeks or months to materialize.
How long before shortages actually hit?
Typical cancer drug stockpiles in the Gulf region run about three months, but some customers have already warned suppliers they could run low within four to six weeks. Shortages in the United States would follow a different and less predictable timeline depending on the specific medication, its source, and its route to market.
Are pharmaceutical companies doing anything to address the disruption?
Yes. Companies are rerouting shipments through alternative hubs including Jeddah, Riyadh, Istanbul, Oman, China, and Singapore. Overland trucking is being used for some Gulf deliveries. Logistics provider Kuehne+Nagel has confirmed that healthcare cargo is being prioritized. However, these alternatives come with tradeoffs in cost, speed, and cold chain reliability.
Should I stockpile my medications?
Panic buying and hoarding typically worsen shortages for everyone. A more reasonable step is to talk to your pharmacist about your specific medication’s supply outlook and ensure you are not letting prescriptions lapse or waiting until the last day to refill. If your medication requires refrigeration or is a specialty drug, ask your provider whether supply disruptions could affect availability in your area.